These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21732248)

  • 41. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of B. anthracis N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening.
    Lei H; Jones C; Zhu T; Patel K; Wolf NM; Fung LW; Lee H; Johnson ME
    Bioorg Med Chem; 2016 Feb; 24(4):596-605. PubMed ID: 26740153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
    Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
    J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Using fragment-based technologies to target protein-protein interactions.
    Bower JF; Pannifer A
    Curr Pharm Des; 2012; 18(30):4685-96. PubMed ID: 22650253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experimental validation of a fragment library for lead discovery using SPR biosensor technology.
    Elinder M; Geitmann M; Gossas T; Källblad P; Winquist J; Nordström H; Hämäläinen M; Danielson UH
    J Biomol Screen; 2011 Jan; 16(1):15-25. PubMed ID: 21149860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosensor-based small molecule fragment screening with biolayer interferometry.
    Wartchow CA; Podlaski F; Li S; Rowan K; Zhang X; Mark D; Huang KS
    J Comput Aided Mol Des; 2011 Jul; 25(7):669-76. PubMed ID: 21660516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural-product-derived fragments for fragment-based ligand discovery.
    Over B; Wetzel S; Grütter C; Nakai Y; Renner S; Rauh D; Waldmann H
    Nat Chem; 2013 Jan; 5(1):21-8. PubMed ID: 23247173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid identification of ligand-binding sites by using an assignment-free NMR approach.
    Kodama Y; Takeuchi K; Shimba N; Ishikawa K; Suzuki E; Shimada I; Takahashi H
    J Med Chem; 2013 Nov; 56(22):9342-50. PubMed ID: 24171460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
    Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
    J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.